Search - tctmd.com

Displaying 601 - 620 of 766

Sort: Relevancy | Date

News Daily News

High Platelet Reactivity Linked to More Adverse Events After Endovascular Procedures

Yael L. Maxwell

April 26, 2013

News Daily News

Bivalirudin Bests Heparin for Lowering Bleeding Risk After CAS

L.A. McKeown

April 26, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

News Conference News ACC 2013

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Jason Kahn

March 11, 2013

News Conference News ACC 2013

STREAM: Fibrinolysis Strategy Effective for STEMI Patients Far From PCI Hospital

Yael L. Maxwell

March 09, 2013

News Conference News ACC 2013

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

Yael L. Maxwell

March 09, 2013

Presentation ACC 2013

Strategies of Clopidogrel Load and Atorvastatin Reload to Prevent Ischemic Cerebral Events in Patients Undergoing Protected Carotid Stenting: Results from the Randomized ARMYDA-9 CAROTID Study

Presenter: Giuseppe Patti

March 08, 2013

News Daily News

Un Subestudio del AIDA STEMI No Confirma Ventaja alguna para el Abciximab Intracoronario

February 27, 2013

News Daily News

AIDA STEMI Substudy Confirms No Advantage for Intracoronary Abciximab

February 27, 2013

News Daily News

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

February 25, 2013

News Daily News

Atorvastatin Boosts Clopidogrel Efficacy in Patients with High Platelet Reactivity

February 25, 2013

Presentation TCT 2013

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Presenter: Salvatore Cassese, Robert Byrne, Tomohisa Tada, Lamin King, Adnan Kastrati

January 31, 2013

Presentation TCT 2013

Switching from Clopidogrel to Prasugrel in Patients Undergoing Coronary Stent Implantation

Presenter: Guido Parodi, Benedetta Bellandi, Vincenzo Comito, Renato Valenti, Nazario Carrabba, Rossella Marcucci, Angela Migliorini, Erica Ramazzotti, Rosanna Abbate, David Antoniucci

January 31, 2013

Presentation TCT 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presenter: Andreas Baumbach, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, Gregg Stone

January 31, 2013

Presentation TCT 2013

P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in Patients with Chest Pain with Prior History of Coronary Artery Stenting in Emergency Department

Presenter: Rakesh Sharma, Stephen Erickson, Rohit Sharma, Hanumanth Reddy, Donald Voelker, Harvinder Dod, Vibhuti Singh, james Marsh

January 31, 2013

Presentation TCT 2013

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

Presenter: Laura Mauri, Gabriel Steg, Alexis Matteau, Edoardo Camenzind, Eric Boersma, Pascal Vranckx, Patrick Serruys, William O'Neill, Robert Yeh, William Wijns

January 31, 2013

Presentation TCT 2013

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Presenter: Renato Valenti, Angela Migliorini, Guido Parodi, Ruben Vergara, Nazario Carrabba, Emilio Vincenzo Dovellini, David Antoniucci

January 31, 2013

News Daily News

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Jason Kahn

January 22, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

Advertisement

High Platelet Reactivity Linked to More Adverse Events After Endovascular Procedures

Bivalirudin Bests Heparin for Lowering Bleeding Risk After CAS

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

STREAM: Fibrinolysis Strategy Effective for STEMI Patients Far From PCI Hospital

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

Strategies of Clopidogrel Load and Atorvastatin Reload to Prevent Ischemic Cerebral Events in Patients Undergoing Protected Carotid Stenting: Results from the Randomized ARMYDA-9 CAROTID Study

Un Subestudio del AIDA STEMI No Confirma Ventaja alguna para el Abciximab Intracoronario

AIDA STEMI Substudy Confirms No Advantage for Intracoronary Abciximab

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

Atorvastatin Boosts Clopidogrel Efficacy in Patients with High Platelet Reactivity

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Switching from Clopidogrel to Prasugrel in Patients Undergoing Coronary Stent Implantation

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in Patients with Chest Pain with Prior History of Coronary Artery Stenting in Emergency Department

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content